The efficacy and safety of Vonoprazan and Tegoprazan in eradication: a comprehensive systematic review and meta-analysis of randomized controlled trials
Background: Potassium-competitive acid blocker (P-CAB)-based therapies are emerging as promising alternatives for eradicating Helicobacter pylori infection. However, the comparative efficacy of P-CAB-based therapy versus proton-pump inhibitor (PPI)-based therapy in treating H. pylori infection remai...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-01-01
|
| Series: | Therapeutic Advances in Gastroenterology |
| Online Access: | https://doi.org/10.1177/17562848251314801 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576053301739520 |
|---|---|
| author | Ting Jin Wei Wu Lei Zhang Han Xuan Haixiang Zhang Li Zhong |
| author_facet | Ting Jin Wei Wu Lei Zhang Han Xuan Haixiang Zhang Li Zhong |
| author_sort | Ting Jin |
| collection | DOAJ |
| description | Background: Potassium-competitive acid blocker (P-CAB)-based therapies are emerging as promising alternatives for eradicating Helicobacter pylori infection. However, the comparative efficacy of P-CAB-based therapy versus proton-pump inhibitor (PPI)-based therapy in treating H. pylori infection remains uncertain. Objectives: This meta-analysis evaluated the efficacy and safety of P-CAB-based therapies, including Vonoprazan (VPZ) and Tegoprazan (TPZ), compared to PPI-based therapies for H. pylori infection. Subgroup analysis assessed the influence of drug history, experimental drug, treatment duration, combination therapies, and geographic regions on treatment outcomes. Design: Meta-analysis. Data sources and methods: Comprehensive searches were conducted in major databases, including PubMed, Embase, the Cochrane Library, and Web of Science, up to January 1, 2024. The primary outcome was the eradication rate, analyzed by intention-to-treat (ITT). Secondary outcomes included adverse events. Heterogeneity among studies was assessed using the χ 2 test and the I 2 test. I 2 > 50% or p < 0.05 indicated significant heterogeneity. Results: The analysis totally included 28 randomized controlled trials (RCTs) comprising 37 studies and 8818 patients diagnosed with H. pylori infection. Of these, 14 RCTs, including 20 studies and 4286 patients, compared P-CAB-based therapy with 14-day bismuth-based quadruple therapy (BQT). P-CAB-based therapy exhibited superior eradication rates compared to both 14-day BQT and PPI-based therapy (ITT analysis: 87.0% vs 79.8%, risk ratio (RR) = 1.08, 95% CI: 1.04–1.12, p < 0.0001; and 85.6% vs 77.8%, RR = 1.09, 95% CI: 1.05–1.12, p < 0.00001, respectively). This enhanced efficacy was particularly pronounced in patients with clarithromycin-resistant infections (73.7% vs 41.5%, RR = 1.53, 95% CI: 1.07–2.20, p = 0.02). Subgroup analysis demonstrated higher eradication rates with P-CAB-based therapy in treatment-naïve participants, VPZ recipients, and those receiving 7- or 14-day regimens (dual, triple, or quadruple therapy). However, no significant differences were observed in treatment-experienced subgroups, TPZ recipients, or those on 10-day regimens. In addition, P-CAB-based therapy showed a lower incidence of adverse events than PPI-based treatments (RR = 0.73, 95% CI: 0.63–0.86, p < 0.0001). Conclusion: P-CAB-based therapies are more effective than traditional PPI-based treatments for eradicating H. pylori infection, with a reduced incidence of adverse events. PROSPERO registration: CRD42024503665. |
| format | Article |
| id | doaj-art-70a3b416c54d42eea1a820d664958f91 |
| institution | Kabale University |
| issn | 1756-2848 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Gastroenterology |
| spelling | doaj-art-70a3b416c54d42eea1a820d664958f912025-01-31T12:04:47ZengSAGE PublishingTherapeutic Advances in Gastroenterology1756-28482025-01-011810.1177/17562848251314801The efficacy and safety of Vonoprazan and Tegoprazan in eradication: a comprehensive systematic review and meta-analysis of randomized controlled trialsTing JinWei WuLei ZhangHan XuanHaixiang ZhangLi ZhongBackground: Potassium-competitive acid blocker (P-CAB)-based therapies are emerging as promising alternatives for eradicating Helicobacter pylori infection. However, the comparative efficacy of P-CAB-based therapy versus proton-pump inhibitor (PPI)-based therapy in treating H. pylori infection remains uncertain. Objectives: This meta-analysis evaluated the efficacy and safety of P-CAB-based therapies, including Vonoprazan (VPZ) and Tegoprazan (TPZ), compared to PPI-based therapies for H. pylori infection. Subgroup analysis assessed the influence of drug history, experimental drug, treatment duration, combination therapies, and geographic regions on treatment outcomes. Design: Meta-analysis. Data sources and methods: Comprehensive searches were conducted in major databases, including PubMed, Embase, the Cochrane Library, and Web of Science, up to January 1, 2024. The primary outcome was the eradication rate, analyzed by intention-to-treat (ITT). Secondary outcomes included adverse events. Heterogeneity among studies was assessed using the χ 2 test and the I 2 test. I 2 > 50% or p < 0.05 indicated significant heterogeneity. Results: The analysis totally included 28 randomized controlled trials (RCTs) comprising 37 studies and 8818 patients diagnosed with H. pylori infection. Of these, 14 RCTs, including 20 studies and 4286 patients, compared P-CAB-based therapy with 14-day bismuth-based quadruple therapy (BQT). P-CAB-based therapy exhibited superior eradication rates compared to both 14-day BQT and PPI-based therapy (ITT analysis: 87.0% vs 79.8%, risk ratio (RR) = 1.08, 95% CI: 1.04–1.12, p < 0.0001; and 85.6% vs 77.8%, RR = 1.09, 95% CI: 1.05–1.12, p < 0.00001, respectively). This enhanced efficacy was particularly pronounced in patients with clarithromycin-resistant infections (73.7% vs 41.5%, RR = 1.53, 95% CI: 1.07–2.20, p = 0.02). Subgroup analysis demonstrated higher eradication rates with P-CAB-based therapy in treatment-naïve participants, VPZ recipients, and those receiving 7- or 14-day regimens (dual, triple, or quadruple therapy). However, no significant differences were observed in treatment-experienced subgroups, TPZ recipients, or those on 10-day regimens. In addition, P-CAB-based therapy showed a lower incidence of adverse events than PPI-based treatments (RR = 0.73, 95% CI: 0.63–0.86, p < 0.0001). Conclusion: P-CAB-based therapies are more effective than traditional PPI-based treatments for eradicating H. pylori infection, with a reduced incidence of adverse events. PROSPERO registration: CRD42024503665.https://doi.org/10.1177/17562848251314801 |
| spellingShingle | Ting Jin Wei Wu Lei Zhang Han Xuan Haixiang Zhang Li Zhong The efficacy and safety of Vonoprazan and Tegoprazan in eradication: a comprehensive systematic review and meta-analysis of randomized controlled trials Therapeutic Advances in Gastroenterology |
| title | The efficacy and safety of Vonoprazan and Tegoprazan in eradication: a comprehensive systematic review and meta-analysis of randomized controlled trials |
| title_full | The efficacy and safety of Vonoprazan and Tegoprazan in eradication: a comprehensive systematic review and meta-analysis of randomized controlled trials |
| title_fullStr | The efficacy and safety of Vonoprazan and Tegoprazan in eradication: a comprehensive systematic review and meta-analysis of randomized controlled trials |
| title_full_unstemmed | The efficacy and safety of Vonoprazan and Tegoprazan in eradication: a comprehensive systematic review and meta-analysis of randomized controlled trials |
| title_short | The efficacy and safety of Vonoprazan and Tegoprazan in eradication: a comprehensive systematic review and meta-analysis of randomized controlled trials |
| title_sort | efficacy and safety of vonoprazan and tegoprazan in eradication a comprehensive systematic review and meta analysis of randomized controlled trials |
| url | https://doi.org/10.1177/17562848251314801 |
| work_keys_str_mv | AT tingjin theefficacyandsafetyofvonoprazanandtegoprazanineradicationacomprehensivesystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT weiwu theefficacyandsafetyofvonoprazanandtegoprazanineradicationacomprehensivesystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT leizhang theefficacyandsafetyofvonoprazanandtegoprazanineradicationacomprehensivesystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT hanxuan theefficacyandsafetyofvonoprazanandtegoprazanineradicationacomprehensivesystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT haixiangzhang theefficacyandsafetyofvonoprazanandtegoprazanineradicationacomprehensivesystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT lizhong theefficacyandsafetyofvonoprazanandtegoprazanineradicationacomprehensivesystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT tingjin efficacyandsafetyofvonoprazanandtegoprazanineradicationacomprehensivesystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT weiwu efficacyandsafetyofvonoprazanandtegoprazanineradicationacomprehensivesystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT leizhang efficacyandsafetyofvonoprazanandtegoprazanineradicationacomprehensivesystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT hanxuan efficacyandsafetyofvonoprazanandtegoprazanineradicationacomprehensivesystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT haixiangzhang efficacyandsafetyofvonoprazanandtegoprazanineradicationacomprehensivesystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT lizhong efficacyandsafetyofvonoprazanandtegoprazanineradicationacomprehensivesystematicreviewandmetaanalysisofrandomizedcontrolledtrials |